Skip to main content
. 2018 Oct 19;54(1):87–97. doi: 10.3892/ijo.2018.4598

Figure 4.

Figure 4

TST inhibits MDA-MB-231 cell growth in vitro. (A) MDA-MB-231 cells were treated with TST at the indicated doses. Cell viability was determined by real-time cell proliferation assay. (B) Cells were treated with 10 µmol/l TST for 48 h. The mRNA expression levels of FOXM1, CCNA2, PLK1, CHEK1, CEP55 and CCNB2 were determined by quantitative polymerase chain reaction. (C) Immunofluorescence staining demonstrated that CDK1, PLK1 and cyclin B1 expression decreased upon treatment. (D) Triple immunofluorescence staining demonstrated that ZEB1 co-localized with vimentin and F-actin, and decreased upon treatment. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs. respective DMSO. TST, Thiostrepton; DMSO, dimethyl sulfoxide; FOXM1, forkhead box M1; CCNA2, cyclin A2; PLK1, polo like kinase 1; CHEK1, checkpoint kinase 1; CEP55, centrosomal protein 55; CCNB2, cyclin B2; ZEB1, zinc finger E-box-binding homeobox 1; F-actin, filamentous actin; CDK1, cyclin-dependent kinase 1.